Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.

Fischer, E. H. Phosphorylase and the origin of reversible protein phosphorylation. Biol. Chem. 391, 131–137 (2010).

pubmed: 20030590

Chandra, H. S. et al. Philadelphia chromosome symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer Genet. 204, 171–179 (2011).

pubmed: 21536234 pmcid: 3092778

Wang, P., Royer, M. & Houtz, R. L. Affinity purification of ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit epsilon N-methyltransferase. Protein Expr. Purif. 6, 528–536 (1995).

pubmed: 8527940

Rothbart, S. B. & Baylin, S. B. Epigenetic therapy for epithelioid sarcoma. Cell 181, 211 (2020).

pubmed: 32302562

Cao, X. J. & Garcia, B. A. Global proteomics analysis of protein lysine methylation. Curr. Protoc. Protein Sci. https://doi.org/10.1002/cpps.16 (2016).

doi: 10.1002/cpps.16 pubmed: 27801517 pmcid: 5222891

Husmann, D. & Gozani, O. Histone lysine methyltransferases in biology and disease. Nat. Struct. Mol. Biol. 26, 880–889 (2019).

pubmed: 31582846 pmcid: 6951022

Ambler, R. P. & Rees, M. W. Epsilon-N-methyl-lysine in bacterial flagellar protein. Nature 184, 56–57 (1959).

pubmed: 13793118

Murray, K. The occurrence of epsilon-N-methyl lysine in histones. Biochemistry 3, 10–15 (1964).

pubmed: 14114491

Rea, S. et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593–599 (2000). This study identfied the first histone lysine methyltransferase and established a connection between histone methylation and epigenetic mechanisms.

pubmed: 10949293

Bannister, A. J. et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410, 120–124 (2001).

pubmed: 11242054

Lachner, M., O’Carroll, D., Rea, S., Mechtler, K. & Jenuwein, T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410, 116–120 (2001).

pubmed: 11242053

Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953 (2004).

pubmed: 15620353

Cornett, E. M., Ferry, L., Defossez, P. A. & Rothbart, S. B. Lysine methylation regulators moonlighting outside the epigenome. Mol. Cell 75, 1092–1101 (2019).

pubmed: 31539507 pmcid: 6756181

Shi, X. et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 442, 96–99 (2006).

pubmed: 16728974 pmcid: 3089773

Wysocka, J. et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442, 86–90 (2006).

pubmed: 16728976

Liu, S. et al. METTL13 methylation of eEF1A increases translational output to promote tumorigenesis. Cell 176, 491–504.e421 (2019). This study established a role for non-histone methylation by METTL13 in the regulation of translational elongation to promote RAS-driven cancers.

pubmed: 30612740 pmcid: 6499081

Andrews, F. H., Strahl, B. D. & Kutateladze, T. G. Insights into newly discovered marks and readers of epigenetic information. Nat. Chem. Biol. 12, 662–668 (2016).

pubmed: 27538025 pmcid: 5116920

Botuyan, M. V. et al. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 127, 1361–1373 (2006).

pubmed: 17190600 pmcid: 1804291

Matthews, A. G. et al. RAG2 PHD finger couples histone H3 lysine 4 trimethylation with V(D)J recombination. Nature 450, 1106–1110 (2007).

pubmed: 18033247 pmcid: 2988437

Vermeulen, M. et al. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell 131, 58–69 (2007).

pubmed: 17884155

Kuo, A. J. et al. The BAH domain of ORC1 links H4K20me2 to DNA replication licensing and Meier-Gorlin syndrome. Nature 484, 115–119 (2012).

pubmed: 22398447 pmcid: 3321094

Wilkinson, A. W. et al. SETD3 is an actin histidine methyltransferase that prevents primary dystocia. Nature 565, 372–376 (2019).

pubmed: 30626964

Kwiatkowski, S. et al. SETD3 protein is the actin-specific histidine N-methyltransferase. eLife 7, e37921 (2018).

pubmed: 30526847 pmcid: 6289574

Lacoste, N., Utley, R. T., Hunter, J. M., Poirier, G. G. & Côte, J. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. J. Biol. Chem. 277, 30421–30424 (2002).

pubmed: 12097318

Ng, H. H., Xu, R. M., Zhang, Y. & Struhl, K. Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. J. Biol. Chem. 277, 34655–34657 (2002).

pubmed: 12167634

van Leeuwen, F., Gafken, P. R. & Gottschling, D. E. Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell 109, 745–756 (2002).

pubmed: 12086673

Feng, Q. et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol. 12, 1052–1058 (2002). This study, along with Lacoste, N. et al., Ng, H. H. et al. & van Leeuwen, F. et al. identified yeast Dot1 as the H3K79 methyltransferase.

pubmed: 12123582

Metzger, E. et al. KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. Nat. Struct. Mol. Biol. 26, 361–371 (2019).

pubmed: 31061526

Falnes, P., Jakobsson, M. E., Davydova, E., Ho, A. & Małecki, J. Protein lysine methylation by seven-β-strand methyltransferases. Biochem. J. 473, 1995–2009 (2016).

pubmed: 27407169

Liu, J. et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 10, 93–95 (2014).

pubmed: 24316715

Barbieri, I. et al. Promoter-bound METTL3 maintains myeloid leukaemia by m

pubmed: 29186125 pmcid: 6217924

Biggar, K. K., Wang, Z. & Li, S. S. SnapShot: lysine methylation beyond histones. Mol. Cell 68, 1016–1016.e1 (2017).

pubmed: 29220647

Li, Y. et al. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J. Biol. Chem. 284, 34283–34295 (2009). This study established the biochemical activity of NSD1, NSD2, NSD3 and SETD2 as H3K36 methyltransferases that have a strong preference for nucleosomal substrates.

pubmed: 19808676 pmcid: 2797197

Kuo, A. J. et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44, 609–620 (2011).

pubmed: 22099308 pmcid: 3222870

Pfister, S. X. & Ashworth, A. Marked for death: targeting epigenetic changes in cancer. Nat. Rev. Drug Discov. 16, 241–263 (2017).

pubmed: 28280262

Schapira, M. Chemical inhibition of protein methyltransferases. Cell Chem. Biol. 23, 1067–1076 (2016).

pubmed: 27569753

Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P. & Reinberg, D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16, 2893–2905 (2002).

pubmed: 12435631 pmcid: 187479

Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039–1043 (2002).

pubmed: 12351676

Müller, J. et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111, 197–208 (2002). This study, along with Kuzmichev, A. et al. & Cao, R. et al. (2002), provided the first descritpion of EZH2 as the H3K27 methyltransferase.

pubmed: 12408864

Cao, R. & Zhang, Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15, 57–67 (2004).

pubmed: 15225548

Pasini, D., Bracken, A. P., Jensen, M. R., Lazzerini Denchi, E. & Helin, K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 23, 4061–4071 (2004).

pubmed: 15385962 pmcid: 524339

Tie, F., Stratton, C. A., Kurzhals, R. L. & Harte, P. J. The N terminus of Drosophila ESC binds directly to histone H3 and is required for E(Z)-dependent trimethylation of H3 lysine 27. Mol. Cell. Biol. 27, 2014–2026 (2007).

pubmed: 17210640 pmcid: 1820504

Margueron, R. et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461, 762–767 (2009).

pubmed: 19767730 pmcid: 3772642

Lee, C. H. et al. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma. Genes Dev. 33, 1428–1440 (2019).

pubmed: 31488577 pmcid: 6771381

Wang, X. et al. Regulation of histone methylation by automethylation of PRC2. Genes Dev. 33, 1416–1427 (2019).

pubmed: 31488576 pmcid: 6771386

Ardehali, M. B. et al. Polycomb repressive complex 2 methylates elongin A to regulate transcription. Mol. Cell 68, 872–884.e876 (2017).

pubmed: 29153392 pmcid: 5800316

Margueron, R. et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32, 503–518 (2008).

pubmed: 19026781 pmcid: 3641558

Kaniskan, H., Martini, M. L. & Jin, J. Inhibitors of protein methyltransferases and demethylases. Chem. Rev. 118, 989–1068 (2018).

pubmed: 28338320

Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).

pubmed: 12374981

Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606–11611 (2003).

pubmed: 14500907 pmcid: 208805

Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat. Med. 22, 128–134 (2016).

pubmed: 26845405 pmcid: 4918227

van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521–523 (2009).

pubmed: 19330029 pmcid: 2873835

Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).

pubmed: 20081860 pmcid: 2850970

Bödör, C. et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 25, 726–729 (2011).

pubmed: 21233829

Sneeringer, C. J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980–20985 (2010).

pubmed: 21078963 pmcid: 3000297

Yap, D. B. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451–2459 (2011).

pubmed: 21190999 pmcid: 3062411

Bödör, C. et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122, 3165–3168 (2013).

pubmed: 24052547 pmcid: 3814734

Majer, C. R. et al. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett. 586, 3448–3451 (2012).

pubmed: 22850114

McCabe, M. T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989–2994 (2012).

pubmed: 22323599 pmcid: 3287005

Kim, K. H. et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21, 1491–1496 (2015).

pubmed: 26552009 pmcid: 4886303

Knutson, S. K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110, 7922–7927 (2013). The first publication describing the EZH2 inhibitor EPZ-6438 (tazemetostat) that subsequently gained FDA approval.

pubmed: 23620515 pmcid: 3651445

Wilson, B. G. et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18, 316–328 (2010).

pubmed: 20951942 pmcid: 2957473

Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203–206 (1998).

pubmed: 9671307

Hasselblatt, M. et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am. J. Surg. Pathol. 35, 933–935 (2011).

pubmed: 21566516

Modena, P. et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res. 65, 4012–4019 (2005).

pubmed: 15899790

Bitler, B. G. et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21, 231–238 (2015).

pubmed: 25686104

Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722–726 (2010).

pubmed: 20601953

Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251–253 (2012).

pubmed: 22286216 pmcid: 3288377

Lewis, P. W. et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340, 857–861 (2013). This study described the dominant negative activity of histone oncomutations, with significant mechanistic implications for pediatric cancers.

pubmed: 23539183 pmcid: 3951439

Mohammad, F. et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat. Med. 23, 483–492 (2017).

pubmed: 28263309

Piunti, A. et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat. Med. 23, 493–500 (2017).

pubmed: 28263307 pmcid: 5667640

Kaniskan, H., Konze, K. D. & Jin, J. Selective inhibitors of protein methyltransferases. J. Med. Chem. 58, 1596–1629 (2015).

pubmed: 25406853

Knutson, S. K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890–896 (2012).

pubmed: 23023262

McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112 (2012). This study, along with Knutson, S. K. et al. (2012), describes the discovery of the first EZH2 inhibitors, which set the stage for tazemetostat to ultimately receive FDA approval as the first KMT inhibitory medicine.

pubmed: 23051747

Jiao, L. & Liu, X. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science 350, aac4383 (2015).

pubmed: 26472914 pmcid: 5220110

Justin, N. et al. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat. Commun. 7, 11316 (2016).

pubmed: 27121947 pmcid: 4853476

Brooun, A. et al. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance. Nat. Commun. 7, 11384 (2016).

pubmed: 27122193 pmcid: 4853478

Kasinath, V. et al. Structures of human PRC2 with its cofactors AEBP2 and JARID2. Science 359, 940–944 (2018).

pubmed: 29348366 pmcid: 5840869

Ciferri, C. et al. Molecular architecture of human polycomb repressive complex 2. eLife 1, e00005 (2012).

pubmed: 23110252 pmcid: 3482686

Vaswani, R. G. et al. Identification of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-cell lymphomas. J. Med. Chem. 59, 9928–9941 (2016).

pubmed: 27739677 pmcid: 5451150

Kung, P. P. et al. Design and synthesis of pyridone-containing 3,4-dihydroisoquinoline-1(2H)-ones as a novel class of enhancer of zeste homolog 2 (EZH2) inhibitors. J. Med. Chem. 59, 8306–8325 (2016).

pubmed: 27512831

Ma, A. et al. Discovery of a first-in-class EZH2 selective degrader. Nat. Chem. Biol. 16, 214–222 (2020).

pubmed: 31819273

Yang, X. et al. Structure-activity relationship studies for enhancer of zeste homologue 2 (EZH2) and enhancer of zeste homologue 1 (EZH1) inhibitors. J. Med. Chem. 59, 7617–7633 (2016).

pubmed: 27468126 pmcid: 5003625

Konze, K. D. et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324–1334 (2013).

pubmed: 23614352 pmcid: 3773059

Zhao, Y. et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 38, (2019).

Kim, J. et al. Polycomb- and methylation-independent roles of EZH2 as a transcription activator. Cell Rep. 25, 2808–2820 e2804 (2018).

pubmed: 30517868 pmcid: 6342284

Zhang, L. et al. Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Sci. Transl Med. 12, eaaz5387 (2020).

pubmed: 32461334 pmcid: 7948522

Morschhauser, F. et al. Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma blood. Blood 134 (Suppl. 1), 123 (2019).

Zauderer, M. G. et al. Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation. J. Clin. Oncol. 36 (Suppl. 15), 8515 (2018).

Stacchiotti, S. et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). J. Clin. Oncol. 37 (Suppl. 15), 11003 (2019).

Gounder, M. M. et al. Immunologic correlates of the abscopal effect in a SMARCB1/INI1-negative poorly differentiated chordoma after EZH2 inhibition and radiotherapy. Clin. Cancer Res. 25, 2064–2071 (2019).

pubmed: 30642912

Taplin, M.-E. et al. Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Res. 79 (Suppl. 13), CT094 (2019).

Yap, T. A. et al. Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin. Cancer Res. 25, 7331–7339 (2019).

pubmed: 31471312 pmcid: 7377921

Xu, B. et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 125, 346–357 (2015).

pubmed: 25395428 pmcid: 4287641

Honma, D. et al. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer Sci. 108, 2069–2078 (2017).

pubmed: 28741798 pmcid: 5623739

Yamagishi, M. et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 29, 2321–2337.e2327 (2019).

pubmed: 31747604

Hansen, K. H. et al. A model for transmission of the H3K27me3 epigenetic mark. Nat. Cell Biol. 10, 1291–1300 (2008).

pubmed: 18931660

Kim, W. et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 9, 643–650 (2013).

pubmed: 23974116 pmcid: 3778130

Xu, C. et al. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). Proc. Natl Acad. Sci. USA 107, 19266–19271 (2010).

pubmed: 20974918 pmcid: 2984210

Qi, W. et al. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nat. Chem. Biol. 13, 381–388 (2017).

pubmed: 28135235

He, Y. et al. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. Nat. Chem. Biol. 13, 389–395 (2017). This study, along with Qi, W. et al., describes the discovery of the first protein–protein interaction disrupting EED inhibitors that function as allosteric inhibitors of PRC2.

pubmed: 28135237

Basheer, F. et al. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. J. Exp. Med. 216, 966–981 (2019).

pubmed: 30890554 pmcid: 6446874

Karantanos, T., Chistofides, A., Barhdan, K., Li, L. & Boussiotis, V. A. Regulation of T cell differentiation and function by EZH2. Front. Immunol. 7, 172 (2016).

pubmed: 27199994 pmcid: 4853381

Qiu, J., Sharma, S., Rollins, R. A. & Paul, T. A. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Med. Chem. https://doi.org/10.4155/fmc-2020-0072 (2020).

doi: 10.4155/fmc-2020-0072 pubmed: 32723083

Hamaidia, M. et al. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism. JCI Insight 4, e128474 (2019).

pmcid: 6795292

Xiao, G. et al. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J. Immunother. Cancer 7, 300 (2019).

pubmed: 31727135 pmcid: 6854886

Zhou, L., Mudianto, T., Ma, X., Riley, R. & Uppaluri, R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents Anti-PD-1 resistance in head and neck cancer. Clin. Cancer Res. 26, 290–300 (2020).

pubmed: 31562203

Goswami, S. et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J. Clin. Invest. 128, 3813–3818 (2018).

pubmed: 29905573 pmcid: 6118570

Zingg, D. et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 20, 854–867 (2017).

pubmed: 28746871

Vlaming, H. & van Leeuwen, F. The upstreams and downstreams of H3K79 methylation by DOT1L. Chromosoma 125, 593–605 (2016).

pubmed: 26728620

Min, J., Feng, Q., Li, Z., Zhang, Y. & Xu, R. M. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 112, 711–723 (2003).

pubmed: 12628190

Jones, B. et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet. 4, e1000190 (2008).

pubmed: 18787701 pmcid: 2527135

Deshpande, A. J. et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell 26, 896–908 (2014).

pubmed: 25464900 pmcid: 4291116

Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78 (2011).

pubmed: 21741597 pmcid: 3329803

Krivtsov, A. V., Hoshii, T. & Armstrong, S. A. Mixed-lineage leukemia fusions and chromatin in leukemia. Cold Spring Harb. Perspect. Med. 7, a026658 (2017).

pubmed: 28242784 pmcid: 5666623

Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167–178 (2005). This study identified a role for human DOT1L, via H3K79 methylation, in promoting MLL-driven leukaemia.

pubmed: 15851025

Mohan, M. et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 24, 574–589 (2010).

pubmed: 20203130 pmcid: 2841335

Chen, S. et al. The PZP domain of AF10 senses unmodified H3K27 to regulate DOT1L-mediated methylation of H3K79. Mol. Cell 60, 319–327 (2015).

pubmed: 26439302 pmcid: 4609290

Li, Y. et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 159, 558–571 (2014).

pubmed: 25417107 pmcid: 4344132

Erb, M. A. et al. Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543, 270–274 (2017).

pubmed: 28241139 pmcid: 5497220

Wan, L. et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature 543, 265–269 (2017).

pubmed: 28241141 pmcid: 5372383

Godfrey, L. et al. DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation. Nat. Commun. 10, 2803 (2019).

pubmed: 31243293 pmcid: 6594956

Briggs, S. D. et al. Gene silencing: trans-histone regulatory pathway in chromatin. Nature 418, 498 (2002).

pubmed: 12152067

McGinty, R. K., Kim, J., Chatterjee, C., Roeder, R. G. & Muir, T. W. Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation. Nature 453, 812–816 (2008).

pubmed: 18449190 pmcid: 3774535

Altaf, M. et al. Interplay of chromatin modifiers on a short basic patch of histone H4 tail defines the boundary of telomeric heterochromatin. Mol. Cell 28, 1002–1014 (2007).

pubmed: 18158898 pmcid: 2610362

Fingerman, I. M., Li, H. C. & Briggs, S. D. A charge-based interaction between histone H4 and Dot1 is required for H3K79 methylation and telomere silencing: identification of a new trans-histone pathway. Genes Dev. 21, 2018–2029 (2007).

pubmed: 17675446 pmcid: 1948857

McGinty, R. K. et al. Structure-activity analysis of semisynthetic nucleosomes: mechanistic insights into the stimulation of Dot1L by ubiquitylated histone H2B. ACS Chem. Biol. 4, 958–968 (2009).

pubmed: 19799466 pmcid: 2785503

Anderson, C. J. et al. Structural basis for recognition of ubiquitylated nucleosome by Dot1L methyltransferase. Cell Rep. 26, 1681–1690.e1685 (2019).

pubmed: 30759380 pmcid: 6392056

Jang, S. et al. Structural basis of recognition and destabilization of the histone H2B ubiquitinated nucleosome by the DOT1L histone H3 Lys79 methyltransferase. Genes Dev. 33, 620–625 (2019).

pubmed: 30923167 pmcid: 6546062

Valencia-Sánchez, M. I. et al. Structural basis of Dot1L stimulation by histone H2B lysine 120 ubiquitination. Mol. Cell 74, 1010–1019.e6 (2019).

pubmed: 30981630 pmcid: 7009778

Worden, E. J., Hoffmann, N. A., Hicks, C. W. & Wolberger, C. Mechanism of cross-talk between H2B ubiquitination and H3 methylation by Dot1L. Cell 176, 1490–1501.e12 (2019).

pubmed: 30765112 pmcid: 6498860

Yao, T. et al. Structural basis of the crosstalk between histone H2B monoubiquitination and H3 lysine 79 methylation on nucleosome. Cell Res. 29, 330–333 (2019).

pubmed: 30770869 pmcid: 6461977

Deshpande, A. J. et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121, 2533–2541 (2013).

pubmed: 23361907 pmcid: 3612861

Daigle, S. R. et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122, 1017–1025 (2013).

pubmed: 23801631 pmcid: 3739029

Krivtsov, A. V. et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355–368 (2008).

pubmed: 18977325 pmcid: 2591932

Gu, Y. et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 71, 701–708 (1992).

pubmed: 1423625

Tkachuk, D. C., Kohler, S. & Cleary, M. L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71, 691–700 (1992).

pubmed: 1423624

Meyer, C. et al. The MLL recombinome of acute leukemias in 2017. Leukemia 32, 273–284 (2018).

pubmed: 28701730

Corral, J. et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85, 853–861 (1996).

pubmed: 8681380

Ayton, P. M. & Cleary, M. L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 17, 2298–2307 (2003).

pubmed: 12952893 pmcid: 196466

Zeisig, B. B. et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol. Cell. Biol. 24, 617–628 (2004).

pubmed: 14701735 pmcid: 343796

Brzezinka, K. et al. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia. J. Hematol. Oncol. 12, 66 (2019).

pubmed: 31253180 pmcid: 6599250

Nguyen, A. T., Taranova, O., He, J. & Zhang, Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117, 6912–6922 (2011).

pubmed: 21521783 pmcid: 3128482

Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53–65 (2011). This study provides the first example of a highly selective histone lysine methyltransferase inhibitor with in vivo efficacy in a cancer model.

pubmed: 21741596 pmcid: 4046888

Chen, L. et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 27, 813–822 (2013).

pubmed: 23138183

Basavapathruni, A. et al. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem. Biol. Drug Des. 80, 971–980 (2012).

pubmed: 22978415

Chen, C. et al. Discovery of novel Dot1L inhibitors through a structure-based fragmentation approach. ACS Med. Chem. Lett. 7, 735–740 (2016).

pubmed: 27563395 pmcid: 4983735

Scheufler, C. et al. Optimization of a fragment-based screening hit toward potent DOT1L inhibitors interacting in an induced binding pocket. ACS Med. Chem. Lett. 7, 730–734 (2016).

pubmed: 27563394 pmcid: 4983739

Shukla, N. et al. Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia. Blood 128, 2780 (2016).

Stein, E. M. et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131, 2661–2669 (2018).

pubmed: 29724899 pmcid: 6265654

Klaus, C. R. et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J. Pharmacol. Exp. Ther. 350, 646–656 (2014).

pubmed: 24993360

Rau, R. E. et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128, 971–981 (2016).

pubmed: 27335278 pmcid: 4990856

Menghrajani, K. et al. A phase Ib/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with 11q23-rearranged acute myeloid leukemia. Blood 134, 2655 (2019).

Secker, K. A. et al. Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9. Oncogene 38, 7181–7195 (2019).

pubmed: 31417187

Skucha, A. et al. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat. Commun. 9, 1983 (2018).

pubmed: 29777171 pmcid: 5959866

Borkin, D. et al. Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 27, 589–602 (2015).

pubmed: 25817203 pmcid: 4415852

Borkin, D. et al. Complexity of blocking bivalent protein-protein interactions: development of a highly potent inhibitor of the menin-mixed-lineage leukemia interaction. J. Med. Chem. 61, 4832–4850 (2018).

pubmed: 29738674 pmcid: 7029623

Tachibana, M., Sugimoto, K., Fukushima, T. & Shinkai, Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J. Biol. Chem. 276, 25309–25317 (2001).

pubmed: 11316813

Tachibana, M. et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 16, 1779–1791 (2002).

pubmed: 12130538 pmcid: 186403

Tachibana, M. et al. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev. 19, 815–826 (2005).

pubmed: 15774718 pmcid: 1074319

Liu, N. et al. Recognition of H3K9 methylation by GLP is required for efficient establishment of H3K9 methylation, rapid target gene repression, and mouse viability. Genes Dev. 29, 379–393 (2015).

pubmed: 25637356 pmcid: 4335294

Collins, R. E. et al. The ankyrin repeats of G9a and GLP histone methyltransferases are mono- and dimethyllysine binding modules. Nat. Struct. Mol. Biol. 15, 245–250 (2008).

pubmed: 18264113 pmcid: 2586904

Tu, W. B. et al. MYC Interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis. Cancer Cell 34, 579–595.e578 (2018).

pubmed: 30300580

Kato, S. et al. Gain-of-function genetic alterations of G9a drive oncogenesis. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-19-0532 (2020).

doi: 10.1158/2159-8290.CD-19-0532 pubmed: 32847940 pmcid: 7334057

Wang, Z. et al. SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy. Cancer Cell 37, 834–849.e13 (2020).

pubmed: 32442403 pmcid: 8187079

Watson, Z. L. et al. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin. Epigenet. 11, 165 (2019).

Maze, I. et al. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science 327, 213–216 (2010).

pubmed: 20056891 pmcid: 2820240

Anderson, E. M. et al. Knockdown of the histone di-methyltransferase G9a in nucleus accumbens shell decreases cocaine self-administration, stress-induced reinstatement, and anxiety. Neuropsychopharmacology 44, 1370–1376 (2019).

pubmed: 30587852

Avgustinova, A. et al. Loss of G9a preserves mutation patterns but increases chromatin accessibility, genomic instability and aggressiveness in skin tumours. Nat. Cell Biol. 20, 1400–1409 (2018).

pubmed: 30455462

Rowbotham, S. P. et al. H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Nat. Commun. 9, 4559 (2018).

pubmed: 30455465 pmcid: 6242814

Kubicek, S. et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25, 473–481 (2007). This study provides the first example of a substrate-competitive, selective lysine methyltransferase inhibitor.

pubmed: 17289593

Dong, C. et al. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J. Clin. Invest. 122, 1469–1486 (2012).

pubmed: 22406531 pmcid: 3314447

Chang, Y. et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol. 16, 312–317 (2009).

pubmed: 19219047 pmcid: 2676930

Vedadi, M. et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 7, 566–574 (2011). This study provided the first example of a selective, cellular chemical probe of G9a/GLP.

pubmed: 21743462 pmcid: 3184254

Liu, F. et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J. Med. Chem. 56, 8931–8942 (2013).

pubmed: 24102134

Sweis, R. F. et al. Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med. Chem. Lett. 5, 205–209 (2014).

pubmed: 24900801 pmcid: 4027767

Xiong, Y. et al. Discovery of potent and selective inhibitors for G9a-like protein (GLP) lysine methyltransferase. J. Med. Chem. 60, 1876–1891 (2017).

pubmed: 28135087 pmcid: 5352984

Ferry, L. et al. Methylation of DNA ligase 1 by G9a/GLP recruits UHRF1 to replicating DNA and regulates DNA methylation. Mol. Cell 67, 550–565.e555 (2017).

pubmed: 28803780

Fang, J. et al. Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr. Biol. 12, 1086–1099 (2002).

pubmed: 12121615

Nishioka, K. et al. PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol. Cell 9, 1201–1213 (2002).

pubmed: 12086618

van Nuland, R. & Gozani, O. Histone H4 lysine 20 (H4K20) methylation, expanding the signaling potential of the proteome one methyl moiety at a time. Mol. Cell Proteom. 15, 755–764 (2016).

Shi, X. et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 27, 636–646 (2007).

pubmed: 17707234 pmcid: 2693209

Kudithipudi, S., Dhayalan, A., Kebede, A. F. & Jeltsch, A. The SET8 H4K20 protein lysine methyltransferase has a long recognition sequence covering seven amino acid residues. Biochimie 94, 2212–2218 (2012).

pubmed: 22583696

McKay, D. J. et al. Interrogating the function of metazoan histones using engineered gene clusters. Dev. Cell 32, 373–386 (2015).

pubmed: 25669886 pmcid: 4385256

Milite, C. et al. The emerging role of lysine methyltransferase SETD8 in human diseases. Clin. Epigenet. 8, 102 (2016).

Couture, J. F., Collazo, E., Brunzelle, J. S. & Trievel, R. C. Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev. 19, 1455–1465 (2005).

pubmed: 15933070 pmcid: 1151662

Xiao, B. et al. Specificity and mechanism of the histone methyltransferase Pr-Set7. Genes Dev. 19, 1444–1454 (2005).

pubmed: 15933069 pmcid: 1151661

Blum, G. et al. Small-molecule inhibitors of SETD8 with cellular activity. ACS Chem. Biol. 9, 2471–2478 (2014).

pubmed: 25137013 pmcid: 4245162

Ma, A. et al. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. J. Med. Chem. 57, 6822–6833 (2014).

pubmed: 25032507 pmcid: 4136711

Ma, A. et al. Structure-activity relationship studies of SETD8 inhibitors. Medchemcomm 5, 1892–1898 (2014).

pubmed: 25554733

Veschi, V. et al. Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy for p53 activation in high-risk neuroblastoma. Cancer Cell 31, 50–63 (2017).

pubmed: 28073004 pmcid: 5233415

Wu, J. et al. Downregulation of histone methyltransferase SET8 inhibits progression of hepatocellular carcinoma. Sci. Rep. 10, 4490 (2020).

pubmed: 32161353 pmcid: 7066161

Butler, K. V. et al. Structure-based design of a covalent inhibitor of the SET domain-containing protein 8 (SETD8) lysine methyltransferase. J. Med. Chem. 59, 9881–9889 (2016).

pubmed: 27804297 pmcid: 5148670

Oda, H. et al. Monomethylation of histone H4-lysine 20 is involved in chromosome structure and stability and is essential for mouse development. Mol. Cell. Biol. 29, 2278–2295 (2009).

pubmed: 19223465 pmcid: 2663305

Pannetier, M. et al. PR-SET7 and SUV4-20H regulate H4 lysine-20 methylation at imprinting control regions in the mouse. EMBO Rep. 9, 998–1005 (2008).

pubmed: 18724273 pmcid: 2525564

Schotta, G. et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 18, 1251–1262 (2004).

pubmed: 15145825 pmcid: 420351

Schotta, G. et al. A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse. Genes Dev. 22, 2048–2061 (2008).

pubmed: 18676810 pmcid: 2492754

Southall, S. M., Cronin, N. B. & Wilson, J. R. A novel route to product specificity in the Suv4-20 family of histone H4K20 methyltransferases. Nucleic Acids Res. 42, 661–671 (2014).

pubmed: 24049080

Wu, H. et al. Molecular basis for the regulation of the H3K4 methyltransferase activity of PRDM9. Cell Rep. 5, 13–20 (2013).

pubmed: 24095733

Gonzalo, S. et al. Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat. Cell Biol. 7, 420–428 (2005).

pubmed: 15750587

Lu, X. et al. The effect of H3K79 dimethylation and H4K20 trimethylation on nucleosome and chromatin structure. Nat. Struct. Mol. Biol. 15, 1122–1124 (2008).

pubmed: 18794842 pmcid: 2648974

Long, H. et al. H2A.Z facilitates licensing and activation of early replication origins. Nature 577, 576–581 (2020).

pubmed: 31875854

Sanders, S. L. et al. Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell 119, 603–614 (2004).

pubmed: 15550243

Yang, H. et al. Preferential dimethylation of histone H4 lysine 20 by Suv4-20. J. Biol. Chem. 283, 12085–12092 (2008).

pubmed: 18296440 pmcid: 2335358

Bromberg, K. D. et al. The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat. Chem. Biol. 13, 317–324 (2017).

pubmed: 28114273

Wang, H. et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol. Cell 8, 1207–1217 (2001).

pubmed: 11779497

Nishioka, K. et al. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 16, 479–489 (2002).

pubmed: 11850410 pmcid: 155346

Lehnertz, B. et al. p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. Mol. Cell 43, 673–680 (2011).

pubmed: 21855805

Barsyte-Lovejoy, D. et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc. Natl Acad. Sci. USA 111, 12853–12858 (2014).

pubmed: 25136132 pmcid: 4156762

Hamidi, T. et al. Identification of Rpl29 as a major substrate of the lysine methyltransferase Set7/9. J. Biol. Chem. 293, 12770–12780 (2018).

pubmed: 29959229 pmcid: 6102145

Komatsu, S. et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br. J. Cancer 112, 357–364 (2015).

pubmed: 25321194

Komatsu, S. et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30, 1139–1146 (2009).

pubmed: 19423649

Reynoird, N. et al. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. Genes Dev. 30, 772–785 (2016).

pubmed: 26988419 pmcid: 4826394

Olsen, J. B. et al. Quantitative profiling of the activity of protein lysine methyltransferase SMYD2 Using SILAC-based proteomics. Mol. Cell Proteom. 15, 892–905 (2016).

Bagislar, S. et al. Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis. Oncotarget 7, 66398–66415 (2016).

pubmed: 27655694 pmcid: 5341809

Cowen, S. D. et al. Design, synthesis, and biological activity of substrate competitive SMYD2 inhibitors. J. Med. Chem. 59, 11079–11097 (2016).

pubmed: 28002961

Ferguson, A. D. et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure 19, 1262–1273 (2011).

pubmed: 21782458

Sweis, R. F. et al. Discovery of A-893, a new cell-active benzoxazinone inhibitor of lysine methyltransferase SMYD2. ACS Med. Chem. Lett. 6, 695–700 (2015).

pubmed: 26101576 pmcid: 4468393

Nguyen, H. et al. LLY-507, a cell-active, potent, and selective inhibitor of protein-lysine methyltransferase SMYD2. J. Biol. Chem. 290, 13641–13653 (2015).

pubmed: 25825497 pmcid: 4447944

Eggert, E. et al. Discovery and characterization of a highly potent and selective aminopyrazoline-based in vivo probe (BAY-598) for the protein lysine methyltransferase SMYD2. J. Med. Chem. 59, 4578–4600 (2016).

pubmed: 27075367 pmcid: 4917279

Huang, J. et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 444, 629–632 (2006).

pubmed: 17108971

Thomenius, M. J. et al. Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLoS ONE 13, e0197372 (2018).

pubmed: 29856759 pmcid: 5983452

Mazur, P. K. et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510, 283–287 (2014). This study identified a role for protein lysine methylation in integrating MAP kinase signalling in the cytoplasm to promote pancreatic and lung cancer.

pubmed: 24847881 pmcid: 4122675

Sarris, M. E., Moulos, P., Haroniti, A., Giakountis, A. & Talianidis, I. Smyd3 Is a transcriptional potentiator of multiple cancer-promoting genes and required for liver and colon cancer development. Cancer Cell 29, 354–366 (2016).

pubmed: 26908355

Hamamoto, R. et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 6, 731–740 (2004).

pubmed: 15235609

Fabini, E. et al. Unveiling the biochemistry of the epigenetic regulator SMYD3. Biochemistry 58, 3634–3645 (2019).

pubmed: 31389685

Van Aller, G. S. et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics 7, 340–343 (2012).

pubmed: 22419068 pmcid: 3368817

Kunizaki, M. et al. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res. 67, 10759–10765 (2007).

pubmed: 18006819

Van Aller, G. S. et al. Structure-based design of a novel SMYD3 inhibitor that bridges the SAM-and MEKK2-binding pockets. Structure 24, 774–781 (2016).

pubmed: 27066749

Mitchell, L. H. et al. Novel oxindole sulfonamides and sulfamides: EPZ031686, the first orally bioavailable small molecule SMYD3 inhibitor. ACS Med. Chem. Lett. 7, 134–138 (2016).

pubmed: 26985287

Huang, C. et al. Discovery of irreversible inhibitors targeting histone methyltransferase, SMYD3. ACS Med. Chem. Lett. 10, 978–984 (2019).

pubmed: 31223458 pmcid: 6580565

Bennett, R. L., Swaroop, A., Troche, C. & Licht, J. D. The role of nuclear receptor-binding SET domain family histone lysine methyltransferases in cancer. Cold Spring Harb. Perspect. Med. 7, a026708 (2017).

pubmed: 28193767 pmcid: 5453381

Yang, S. et al. Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase. Genes Dev. 30, 1611–1616 (2016).

pubmed: 27474439 pmcid: 4973290

Böttcher, J. et al. Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3. Nat. Chem. Biol. 15, 822–829 (2019).

pubmed: 31285596

Sun, Y. et al. Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion. Asian J. Androl. 16, 319–324 (2014).

pubmed: 24556744 pmcid: 3955348

Wong, C. M. et al. Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology 63, 474–487 (2016).

pubmed: 26481868

Zhu, Y., Sun, D., Jakovcevski, M. & Jiang, Y. Epigenetic mechanism of SETDB1 in brain: implications for neuropsychiatric disorders. Transl Psychiatry 10, 115 (2020).

pubmed: 32321908 pmcid: 7176658

Kim, Y., Wang, S. E. & Jiang, Y. H. Epigenetic therapy of Prader-Willi syndrome. Transl Res. 208, 105–118 (2019).

pubmed: 30904443 pmcid: 6527448

Woodcock, C. B., Yu, D., Zhang, X. & Cheng, X. Human HemK2/KMT9/N6AMT1 is an active protein methyltransferase, but does not act on DNA in vitro, in the presence of Trm112. Cell Discov. 5, 50 (2019).

pubmed: 31632689 pmcid: 6796829

Kusevic, D., Kudithipudi, S. & Jeltsch, A. Substrate specificity of the HEMK2 protein glutamine methyltransferase and identification of novel substrates. J. Biol. Chem. 291, 6124–6133 (2016).

pubmed: 26797129 pmcid: 4813560

Figaro, S., Scrima, N., Buckingham, R. H. & Heurgué-Hamard, V. HemK2 protein, encoded on human chromosome 21, methylates translation termination factor eRF1. FEBS Lett. 582, 2352–2356 (2008).

pubmed: 18539146

Allali-Hassani, A. et al. Discovery of a chemical probe for PRDM9. Nat. Commun. 10, 5759 (2019). This study describes the first inhibitor of PRDM9, a potential target in multiple cancers.

pubmed: 31848333 pmcid: 6917776

Houle, A. A. et al. Aberrant PRDM9 expression impacts the pan-cancer genomic landscape. Genome Res. 28, 1611–1620 (2018).

pubmed: 30341163 pmcid: 6211651

Powers, N. R. et al. The meiotic recombination activator PRDM9 trimethylates both H3K36 and H3K4 at recombination hotspots in vivo. PLoS Genet. 12, e1006146 (2016).

pubmed: 27362481 pmcid: 4928815

Mzoughi, S., Tan, Y. X., Low, D. & Guccione, E. The role of PRDMs in cancer: one family, two sides. Curr. Opin. Genet. Dev. 36, 83–91 (2016).

pubmed: 27153352

Roqueta-Rivera, M. et al. SETDB2 links glucocorticoid to lipid metabolism through Insig2a regulation. Cell Metab. 24, 474–484 (2016).

pubmed: 27568546 pmcid: 5023502

Sessa, A. et al. SETD5 regulates chromatin methylation state and preserves global transcriptional fidelity during brain development and neuronal wiring. Neuron 104, 271–289.e213 (2019).

pubmed: 31515109

Mas, Y. M. S. et al. The human mixed lineage leukemia 5 (MLL5), a sequentially and structurally divergent set domain-containing protein with no intrinsic catalytic activity. PLoS ONE 11, e0165139 (2016).

Robichaud, N., Sonenberg, N., Ruggero, D. & Schneider, R. J. Translational control in cancer. Cold Spring Harb. Perspect. Biol. 11, 254–266 (2019).

Jakobsson, M. E., Małecki, J. & Falnes, P. Regulation of eukaryotic elongation factor 1 alpha (eEF1A) by dynamic lysine methylation. RNA Biol. 15, 314–319 (2018).

pubmed: 29447067 pmcid: 5927720

Jakobsson, M. E. et al. Methylation of human eukaryotic elongation factor alpha (eEF1A) by a member of a novel protein lysine methyltransferase family modulates mRNA translation. Nucleic Acids Res. 45, 8239–8254 (2017).

pubmed: 28520920 pmcid: 5737405

Davydova, E. et al. Identification and characterization of a novel evolutionarily conserved lysine-specific methyltransferase targeting eukaryotic translation elongation factor 2 (eEF2). J. Biol. Chem. 289, 30499–30510 (2014).

pubmed: 25231979 pmcid: 4215231

Zhang, L., Hamey, J. J., Hart-Smith, G., Erce, M. A. & Wilkins, M. R. Elongation factor methyltransferase 3 – a novel eukaryotic lysine methyltransferase. Biochem. Biophys. Res. Commun. 451, 229–234 (2014).

pubmed: 25086354

Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Subventions

Références

Auteurs

Kamakoti P Bhat (KP)

H Ümit Kaniskan (H)

Jian Jin (J)

Or Gozani (O)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH